Stocks and Investing Stocks and Investing
Fri, September 6, 2019

Chris Schott Maintained (TEVA) at Sell with Decreased Target to $7 on, Sep 6th, 2019


Published on 2024-10-26 16:00:06 - WOPRAI, Chris Schott
  Print publication without navigation


Chris Schott of JP Morgan, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $9 to $7 on, Sep 6th, 2019.

Chris has made no other calls on TEVA in the last 4 months.



There are 6 other peers that have a rating on TEVA. Out of the 6 peers that are also analyzing TEVA, 3 agree with Chris's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Vamil Divan of "Credit Suisse" Initiated at Hold on, Wednesday, July 10th, 2019
  • Kevin Caliendo of "UBS" Downgraded from Strong Buy to Hold and Decreased Target to $12 on, Tuesday, May 28th, 2019
  • Jacob Hughes of "Wells Fargo" Maintained at Hold with Decreased Target to $17 on, Thursday, May 9th, 2019


These are the ratings of the 3 analyists that currently disagree with Chris


  • David Risinger of "Morgan Stanley" Downgraded from Hold to Sell and Decreased Target to $6 on, Monday, July 15th, 2019
  • Douglas Tsao of "Barclays" Initiated at Sell and Held Target at $8 on, Tuesday, June 11th, 2019
  • Jason Gerberry of "B of A Securities" Downgraded from Strong Buy to Sell and Decreased Target to $9 on, Thursday, May 30th, 2019
Contributing Sources